Posts Tagged 'actos recall'

Judge allows company to sell generic Actos

A U.S. District Judge has allowed a company to begin immediately selling generic Actos, despite resistance from the Food and Drug Administration (FDA). Watson Pharmaceuticals will begin marketing the generic version of the top-selling type II diabetes drug Actos, which has come under fire for health concerns.

Read more about the generic version of Actos…


Judge sets 1st hearing for diabetes drug lawsuits

A federal judge in Louisiana has scheduled an initial court hearing for a batch of lawsuits that claim Takeda Pharmaceuticals’ top-selling diabetes drug, Actos, carries an increased risk of bladder cancer. Takeda’s Japanese parent company, Takeda Pharmaceuticals Co. Ltd., halted sales of Actos in Germany and France last year.

Click here to read more…

FDA approves new Actos bladder cancer warning

The Food and Drug Administration has approved a new warning about the link between the diabetes drug Actos and bladder cancer. The agency called for the new warning after a study found that patients who use Actos for at least one year are 40% more likely to develop bladder cancer.

Click here to read more…

FDA Mulling End to Avandia-Actos Trial on Safety Worries

The FDA is considering cutting short a trial comparing the safety of two diabetes drugs — GlaxoSmithKline’s Avandia and Takeda’s Actos, the WSJ reports. Given that Avandia has been linked since 2007 to an increased risk of heart attacks, some scientists have said it’s not ethical to put study participants at risk. If the trial is stopped, the FDA will also consider asking Glaxo to stop selling the drug.

Click here to read more…

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 437 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101


Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.